Follicular lymphoma is a complex blood cancer that originates from white blood cells in the lymphatic system. When this disease returns after treatment or stops responding to therapy, it enters a phase called relapsed or refractory disease, bringing unique challenges that require careful medical attention and thoughtful treatment decisions.

Understanding Follicular Lymphoma: The Basics

Follicular lymphoma is a type of blood cancer that develops when certain white blood cells called lymphocytes, which normally help fight infections, begin to grow out of control. These abnormal cells are a specific type of white blood cell known as B cells, and they gather together in clusters or “follicles” inside structures called lymph nodes, which are small bean-shaped organs scattered throughout the body as part of the immune system.^[1][2]

This disease is classified as a non-Hodgkin lymphoma, meaning it’s one of several cancer types affecting the lymphatic system but distinct from Hodgkin lymphoma. Follicular lymphoma stands out as the second most common form of non-Hodgkin lymphoma overall and the most frequently diagnosed among the slower-growing, or indolent, types of lymphoma.^[1][8]

The cancerous B cells in follicular lymphoma come from what’s known as germinal center cells within lymph nodes. These include two types of cells: centrocytes (smaller cleaved cells) and centroblasts (larger non-cleaved cells). The disease gets its name from the follicular, or nodular, growth pattern these abnormal cells typically form when they cluster together.^[1][5]

Epidemiology: Who Gets Follicular Lymphoma?

Follicular lymphoma represents approximately 20 to 30 percent of all non-Hodgkin lymphoma cases in the United States and Europe, making it a significant portion of lymphoma diagnoses.^[6][8] In the United States alone, there are about 15,000 to 20,000 new diagnoses of follicular lymphoma each year.^[7]

The disease shows a clear pattern in terms of who it affects. It occurs equally in men and women, with no sex preponderance reported, but the likelihood of developing follicular lymphoma increases significantly with age.^[8] The median age at diagnosis is around 59 to 63 years, meaning most people are in their early to mid-sixties when they first learn they have the disease.^[12][3]

The incidence of follicular lymphoma also varies across different racial and ethnic groups. The disease is most common among white individuals, and the annual incidence has remained relatively stable over time at approximately 3.18 cases per 100,000 people.^[13]

When it comes to long-term survival, follicular lymphoma has seen improvements over the years. Historically, the median survival was approximately 8 to 10 years, but with newer treatments developed since the introduction of rituximab (an important medication used to treat this disease), overall survival has increased further. More than 90 percent of patients survive beyond 5 years of initial diagnosis, and the median overall survival is now around 14 years.^[8][12]

Causes: What Leads to Follicular Lymphoma?

The exact causes of follicular lymphoma remain unclear, and in many cases, no specific cause can be identified.^[3] However, researchers have identified several key biological changes that appear to drive the development of this disease.

A hallmark characteristic of follicular lymphoma is a specific genetic abnormality called the t(14;18) translocation, which occurs in about 85 to 90 percent of cases. This chromosomal change happens when pieces of two different chromosomes swap places during a normal process of immune cell development.^[1][8] The translocation causes a gene called BCL2 to be placed next to another gene called IGH (immunoglobulin heavy chain gene). This repositioning causes the BCL2 gene to become overactive, producing too much of a protein called Bcl-2. This protein helps cells survive by preventing them from dying naturally, which is a process called apoptosis. When cells that should die continue to survive and multiply, cancer can develop.^[1]

Interestingly, the t(14;18) translocation alone doesn’t cause follicular lymphoma to develop. Scientists have found that t(14;18)-positive cells can exist in healthy people who never develop lymphoma. However, having a high frequency of these cells in the blood appears to increase the risk of eventually developing follicular lymphoma years later.^[8]

Beyond the BCL2 change, researchers have discovered that mutations in genes responsible for modifying how DNA is packaged and expressed (called epigenetic modifications) are common in follicular lymphoma. These “epimutations” affect genes including KMT2D, CREBBP, and EZH2, which help control how other genes are turned on or off. These mutations are considered a second defining characteristic of follicular lymphoma.^[1][5]

It’s important to note that these genetic changes happen at some point during a person’s lifetime and are not inherited from parents. Follicular lymphoma is not a condition passed down through families.^[7]

Risk Factors: Who Is More Likely to Develop This Disease?

Several factors may increase a person’s risk of developing follicular lymphoma, though having these risk factors doesn’t mean someone will definitely get the disease.

Age is one of the strongest risk factors. People aged 65 and older are significantly more likely to develop follicular lymphoma compared to younger individuals.^[7] The disease can occur in children, but pediatric follicular lymphoma is so different from the adult form that researchers consider it an entirely separate type of cancer. Unlike adult follicular lymphoma, the childhood version is often curable.^[7]

Race and ethnicity play a role, with white individuals receiving this diagnosis more frequently than people of other racial backgrounds.^[1][13]

Certain medical conditions affecting the immune system may increase risk. People living with HIV, rheumatoid arthritis, lupus, or celiac disease—all of which are immune system disorders—may have a higher chance of developing follicular lymphoma.^[3][8] Similarly, individuals who have received organ transplants and take immunosuppressant medications to prevent rejection, or those with congenital immunodeficiencies, face increased risk, though the lymphomas associated with these conditions are often more aggressive types.^[8]

Having a family history of lymphoma may also increase risk.^[3] Additionally, exposure to certain chemicals in the workplace, such as defoliants like Agent Orange or hair dyes, has been associated with lymphoma risk, though these chemicals are more strongly linked to aggressive lymphoma types.^[8]

Various viruses have been implicated in lymphoma development, including Epstein-Barr virus, human T-cell lymphotropic virus type I, human herpesvirus-8, and hepatitis B and C viruses. However, these viruses are mostly connected to diffuse or high-grade lymphomas rather than follicular lymphoma specifically.^[8]

Symptoms: What Does Follicular Lymphoma Feel Like?

Follicular lymphoma is known for being a slow-growing cancer, and many people with this disease don’t experience any symptoms at all when it’s first discovered. In fact, the lymphoma is sometimes found during routine blood work or imaging tests done for completely unrelated reasons.^[6][8]

When symptoms do appear, they often develop gradually over time. The most common and typically first sign is painless swelling of lymph nodes in the neck, armpit, or groin. These swollen nodes are persistent, meaning they don’t go away on their own, and they continue to grow slowly over weeks or months.^[3][6][7]

Other symptoms that may occur include fatigue or a general feeling of tiredness that doesn’t improve with rest. Some people experience unexplained weight loss, particularly losing 10 percent or more of their body weight over the past six months without trying to diet or change eating habits.^[3][6][7]

Night sweats—episodes of sweating during sleep that may be severe enough to soak through nightclothes and bedding—are another possible symptom. Fever without any signs of infection can also occur. Some people may feel chills or experience shortness of breath, especially if the lymphoma affects lymph nodes in the chest.^[3][8]

When lymph nodes or the spleen become enlarged in the abdomen, a person might feel full quickly while eating or experience abdominal discomfort. If the spleen enlarges significantly, it may cause a feeling of fullness or pressure in the upper left part of the belly.^[6][7]

Because follicular lymphoma affects the immune system, some people experience recurring infections due to weakened immune function.^[6] In more advanced stages, if the disease affects bone marrow (where blood cells are made), symptoms related to low blood cell counts may develop, such as anemia (causing fatigue), leukopenia (low white blood cells leading to infections), or thrombocytopenia (low platelets causing easy bruising or bleeding). However, these bone marrow-related symptoms are rare at initial diagnosis and typically occur only in later stages.^[8]

Prevention: Can Follicular Lymphoma Be Prevented?

Currently, there are no proven strategies to prevent follicular lymphoma. Because the exact causes of the disease remain unclear and the genetic changes that lead to follicular lymphoma occur spontaneously during a person’s lifetime rather than being inherited, there aren’t specific preventive measures like vaccinations or lifestyle changes that can reliably stop the disease from developing.^[3]

For people who have certain risk factors, such as autoimmune diseases or those taking immunosuppressive medications after organ transplants, regular medical monitoring may help with early detection, but this doesn’t prevent the disease from occurring. Similarly, while avoiding known chemical exposures associated with lymphoma risk (such as certain workplace chemicals) may theoretically reduce risk, there’s no guarantee this will prevent follicular lymphoma specifically.^[8]

The emphasis in follicular lymphoma is on early detection and appropriate management rather than prevention. If you have risk factors or develop persistent symptoms like swollen lymph nodes, seeking medical evaluation promptly is important. Early diagnosis and careful monitoring, even without immediate treatment, can lead to better long-term outcomes.^[6]

Pathophysiology: How the Disease Affects the Body

Follicular lymphoma begins in B cells that are part of the germinal centers within lymph nodes. Germinal centers are specialized areas where B cells normally go to mature and develop the ability to produce antibodies that fight infections. In follicular lymphoma, something goes wrong during this maturation process.^[1][5]

Scientists believe the disease process begins very early in precursor B cells located in the bone marrow. These immature cells acquire the t(14;18) translocation during normal immune system development. The translocation happens during a process called V(D)J recombination, which is how B cells naturally rearrange their genes to create diverse antibodies. In follicular lymphoma, this process goes awry, causing the BCL2 gene to relocate next to the IGH gene.^[1][5]

After acquiring this initial genetic change, the affected B cells migrate from the bone marrow to lymph nodes, where they continue their maturation through the germinal center reaction. During this time in the lymph nodes, the cells acquire additional genetic and epigenetic abnormalities that further promote cancer development. These additional changes include mutations in genes that control how DNA is packaged and how genes are turned on or off.^[5]

The BCL2 protein produced by the translocated gene prevents cells from undergoing apoptosis (programmed cell death), which is the body’s normal way of removing old or damaged cells. When these abnormal B cells can’t die naturally, they accumulate and continue to divide, leading to the formation of tumors.^[1][8]

As follicular lymphoma progresses, the abnormal B cells typically grow in a follicular or nodular pattern that mimics the structure of normal germinal centers, which is why the disease is called “follicular” lymphoma. The cells can spread to multiple lymph node groups throughout the body, and in many cases, they also spread to the bone marrow, spleen, and blood. By the time most people are diagnosed, the disease has already spread to multiple areas of the body, with most patients having Stage III or IV disease.^[2][7]

Despite being widespread, follicular lymphoma typically grows slowly due to its indolent nature. The cells divide at a slower rate compared to aggressive lymphomas, which is why many people can have the disease for months or years without symptoms. The tumor cells in follicular lymphoma express markers that show their germinal center origin, including proteins called CD10, BCL2, and BCL6, while typically lacking certain other markers like CD5 and CD43.^[13]

In some cases, follicular lymphoma can undergo a transformation into a more aggressive type of lymphoma, most commonly diffuse large B-cell lymphoma. This transformation involves the acquisition of additional genetic changes that cause the cells to grow faster and behave more aggressively. When this happens, the disease course changes significantly, requiring different and more intensive treatment approaches.^[1][7]

Understanding Relapsed and Refractory Follicular Lymphoma

Follicular lymphoma is generally considered an incurable disease, which means that while treatments can control it effectively, the cancer often returns at some point. When the disease comes back after treatment, it’s called relapsed follicular lymphoma. When the disease doesn’t respond to treatment at all or the response doesn’t last very long, it’s described as refractory follicular lymphoma.^[18]

The disease follows what doctors call a “relapsing and remitting course,” meaning it goes through cycles of responding to treatment (remission) and then returning (relapse). This pattern can continue over many years, with patients needing intermittent therapy throughout decades of living with the condition.^[1]

Although many patients achieve remission that lasts for years after their initial treatment, the disease often returns eventually. For patients who relapse, second-line therapies (treatments given when the first treatment stops working) are often successful in achieving another remission. The challenge is that with each subsequent relapse, the duration of response may become shorter, though this isn’t always the case.^[18]

Not everyone who experiences relapse needs immediate treatment. If the relapsed disease isn’t causing symptoms, doctors may recommend an approach called “active surveillance,” also known as “watch and wait” or “watchful waiting.” With this strategy, the patient’s overall health and disease are monitored through regular checkup visits and various tests, such as blood work and imaging scans. Active treatment is started only if the patient begins developing lymphoma-related symptoms or if tests show that the disease is progressing rapidly.^[1][18]

When treatment for relapsed or refractory follicular lymphoma is needed, several factors influence the choice of therapy. These include the patient’s age, overall health status, the presence of other medical conditions (comorbidities), current symptoms, how well the patient can perform daily activities (performance status), how much disease is present (disease burden), and how long the remission lasted from the previous treatment.^[1][18]

Many of the same therapies used for newly diagnosed patients can also be used to treat relapsed or refractory disease. These include various combinations of chemotherapy, immunotherapy drugs, targeted therapy medications, and radiation therapy. However, additional treatment options are also available specifically for patients whose disease has returned or never responded well to initial therapy.^[18]

For third-line treatment (treatment given when both first and second treatments have failed), there is no single established standard of care. Doctors must choose from several different types of therapies with varying safety profiles, dosing schedules, and effectiveness. The selection depends heavily on individual patient factors, such as whether the patient is elderly with multiple other health conditions, or younger with disease that progressed quickly, as well as patient preferences regarding treatment schedules and quality of life considerations.^[12]

Newer therapeutic approaches for relapsed or refractory follicular lymphoma include targeted medications that work in specific ways to fight the cancer, such as drugs called PI3K inhibitors and EZH2 inhibitors. More recently, advanced immunotherapy approaches like CAR T-cell therapy, which involves modifying a patient’s own immune cells to recognize and attack lymphoma cells, have become available for certain patients with relapsed or refractory disease.^[1][18]

Living with relapsed or refractory follicular lymphoma presents unique challenges. The disease’s chronic nature means patients and their families must adapt to a long-term relationship with cancer and its treatments. Quality of life considerations become increasingly important as the disease goes through multiple relapses, and many patients benefit from support services, including coordination with oncology nurse navigators who help manage the complexities of care across multiple treatment lines.^[12]